Revolutionary fully implanted hearing device tested in adults
NCT ID NCT06699797
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a fully implanted cochlear implant called Acclaim CI in 56 adults with severe to profound hearing loss. The goal is to see if it helps them hear words better than before and to check for any medical problems. Participants get the implant and are followed for up to 2 years.
Why investors are watching
Envoy Medical is a very small publicly traded company, and this trial is its main event. The study tests whether its fully implanted Acclaim cochlear implant helps adults with severe to profound hearing loss recognize words better than before surgery, and whether the device is safe. For a micro-cap company, the outcome of this 56-patient trial could determine the value of its entire pipeline.
If it works: If the trial shows clear word-recognition gains and an acceptable safety profile, Envoy could have a marketable product in a field where fully implanted devices are rare. That result might attract partners or funding to bring the device through regulatory approval.
If it fails: Clinical trials often fail to show meaningful benefit or reveal unexpected safety problems. A negative or delayed result could leave Envoy without a clear path to revenue, which would be a serious setback for a company of its size.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 56 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Signed and dated informed consent form. 2. Able to understand and comply with the requirements of the Study, including surgery and post-implant rehabilitation. 3. Ability to read, write, comprehend, and speak fluently in English. 4. Post-lingually deafened. 5. 18 years of age or older at the time of informed consent. 6. Good health and absence of significant comorbidities, in the opinion of the Principal Investigator. 7. At least 30 days of experience with appropriate bilaterally fit hearing aids. 8. Ear to be implanted has severe to profound hearing loss defined as pure tone average at 500, 1000, 2000 and 4000 Hz ≥ 70 dB. 9. Contralateral ear has moderately severe to profound hearing loss defined as pure tone average at 500, 1000, 2000 and 4000 Hz ≥ 60 dB. 10. Limited benefit from amplification defined as CNC monosyllabic word recognition ≤ 40% in the ear to be implanted and ≤ 60% in the contralateral ear, in the aided condition. 11. Normal middle ear function based on otoscopy and tympanometry. 12. An accessible cochlear lumen and intact cochlear nerve, and no known lesions on the auditory nerve or auditory central nervous system, on the ear to be implanted confirmed with MRI or CT scan. Exclusion Criteria: 1. Documented duration of severe to profound hearing loss for 20 or more years. 2. Previous cochlear implantation in either ear. 3. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array. 4. Active external or middle ear pathology (i.e., infections, tympanic membrane perforation, or ossicular chain issues) in the ear to be implanted at the time of screening or in the past 6 months, that could impact the proper functioning of the device. 5. Known history of chronic eustachian tube dysfunction. 6. Prior surgery in the middle ear, inner ear, neck, or infraclavicular region which is anticipated to prevent proper placement or function of the Acclaim CI. 7. Hearing loss/disorder of retrocochlear origin. 8. Diagnosis of auditory neuropathy. 9. Currently using other active implants that are expected to interfere with the Acclaim CI position or function. 10. Known hypersensitivity to silicone rubber, polyurethane, stainless steel, titanium, platinum, or gold. 11. Known hypersensitivity or contraindications to procedural or post-procedural medications that cannot be adequately managed medically. 12. Pregnancy at the time of Acclaim CI implantation. 13. Known need for MRI or ionizing radiation treatment during Study participation. 14. Unrealistic expectations on the Participant's part regarding the possible benefits, risks, and limitations inherent to the surgical procedure and use of the Acclaim CI, in the Principal Investigator's opinion. 15. Unwillingness or inability to comply with all investigational requirements. 16. Additional conditions that would prevent completion of all Study requirements, in the opinion of the Principal Investigator. 17. Participation in an investigational drug study or another device study within 3 months of the Screening Visit. 18. Previous history of meningitis. 19. Deafness, in the ear to be implanted, due to: 1. a damaged or absent tympanic membrane, 2. a damaged or absent middle ear, 3. an absent cochlea, 4. lesions on the acoustic nerve, or 5. lesions on the central auditory pathway
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sensori-neural deafness are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Neurosciences Ear and Hearing Center
Tucson, Arizona, 85718, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Hearts for Hearing
Oklahoma City, Oklahoma, 73114, United States
-
MUSC Health
Charleston, South Carolina, 29425, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
-
Shohet Ear Associates
Seal Beach, California, 90740, United States
-
University of Florida Health
Gainesville, Florida, 32607, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could talking it out boost hearing aid success?
- Is hearing loss becoming a bigger cause of disability? a national study digs into the data
- Can an antiviral drug protect hearing in infants with congenital CMV?
- Could a new test help hearing aid users hear better in crowds?
- CT-Guided tuning: a new way to Fine-Tune cochlear implants?
- Could an app tune your hearing aids as well as an audiologist?